Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network

Go back to Newsroom

Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network

Emmes awarded multi-task, IDIQ contract with $50M ceiling, to support NIDA’s clinical trials network
Emmes, part of Emmes Group, today announced they will provide a Clinical Coordinating Center for the NIH's National Institute on Drug Abuse Clinical Trials

Download Go back to Newsroom

Technology in Vaccine Trials

Go back to Blog

In the wake of the COVID-19 pandemic, the world has witnessed both the devastating impact of infectious diseases and the remarkable speed at which vaccines can be developed and deployed. This unprecedented crisis has underscored the need for rapid vaccine clinical trials, driven by a combination of factors: maximizing public benefits, ensuring cost-effective clinical development, and securing a competitive edge in the pharmaceutical industry.

Download Go back to Blog

Emmes Group® names Germaine Gross Chief Commercial Officer of Emmes® Biopharma

Go back to Newsroom

Emmes Group® names Germaine Gross Chief Commercial Officer of Emmes® Biopharma

Strategic hire underscores Emmes Group’s growth and commitment to biopharma market

Emmes Group®, a leading specialty tech and AI-enabled global contract research organization (CRO), today announced the appointment of Germaine Gross to the role of Chief Commercial Officer, Emmes® Biopharma. This strategic hire underscores the company’s commitment to expanding its biopharma footprint, fostering innovation, and redefining excellence in the CRO industry.

Download Go back to Newsroom

Newsroom

The Emmes Group Newsroom features updates on the work we’re doing to advance clinical research and public health. Here you’ll find news about partnerships, contract awards, technology innovations, leadership appointments, industry recognition, and expert perspectives.

Our History

Who We Are

At Emmes Group, our work is driven by a simple but profound belief: truth matters. Since our founding in 1977, we’ve been committed to uncovering truth in clinical research - through scientific rigor, operational excellence, and deep collaboration with our clients and partners.

Emmes Group by the Numbers

At Emmes Group, numbers tell a story of lasting impact. For nearly five decades, we’ve supported the world’s most complex clinical trials with scientific rigor, global reach, and cutting-edge technology. Our key metrics reflect not only the scale of our operations, but also the trust placed in us by leading sponsors, government agencies, and researchers around the world. These numbers are more than stats—they represent our commitment to uncovering the truth behind medical innovation.

Biostats and Analysis Agent

The Veridix Biostats and Analysis Agent empowers biostatistics teams to deliver faster, cleaner, and more consistent outputs across the trial lifecycle. By automating TFL shell creation, interim analyses, and final reports, the agent eliminates repetitive formatting and QC tasks, reduces handoffs between teams, and accelerates time to insight. Built for scale, it brings greater efficiency and control to everything from DSMB packages to CSR-ready outputs - without disrupting your existing workflows.

Veridix

veridix home

Technology and AI Platform

Providing the Technology, Data, Analytical and AI capabilities to modernize and automate clinical research within Emmes and across the industry​.

Making effective use of the compl

Subscribe to